Sparsomycin

Last updated
Sparsomycin
Sparsomycin.png
Identifiers
  • (E)-N-[1-hydroxy-3-(methylsulfanylmethylsulfinyl)propan-2-yl]-3-(6-methyl-2,4-dioxo-1H-pyrimidin-5-yl)prop-2-enamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C13H19N3O5S2
Molar mass 361.43 g·mol−1
3D model (JSmol)
  • O=C1N/C(=C(/C=C/C(=O)NC(CS(=O)CSC)CO)C(=O)N1)C

Sparsomycin is a compound, initially discovered as a metabolite of the bacterium Streptomyces sparsogenes , which binds to the 50S ribosomal subunit and inhibits protein synthesis through peptidyl transferase inhibition. [1] As it binds to the 50S ribosomal subunit, it induces translocation on the 30S subunit. [2] It is a nucleotide analogue. It was also formerly thought to be a possible anti-tumor agent, but interest in this drug was later discarded after it was discovered that it resulted in retinopathy [3] and as a tool to study protein synthesis; it is not specific for bacterial ribosomes and so not usable as an antibiotic.

The compound was discovered in 1962 [4] and the structure was determined in 1970; [5] a first total synthesis was reported in 1981. [6]

A derivative of this compound is phenol-alanine-sparsomycin, and is believed to be a more effective anti-tumor agent than sparsomycin itself. [3]

Biosynthesis

Although the structure of sparsomycin was published in 1970, no biosynthetic pathway for its formation was proposed in the literature up until 1988. Ronald J. Parry et al. have investigated biosynthetical precursors for the unusual monooxo-dithioacetal group. [7] By administering the radioactively labeled L-methionine to S. sparsogenes, they figured out that it was the most probable precursor for C-4' and C-5' atoms of the sparsomycin. However, when administering labeled cysteine, they found that C-4' did not contain any 13C while C-3' still did. This finding led them to an assumption that an enzyme called serine transhydroxymethylase could be responsible for the observation by conversion of the cysteine to serine residue. However, this assumption was not confirmed, as administration of 13C-serine did not produce any labeled sparsomycin. In this study the authors have finally concluded that S-methyl-D-cysteine should be the precursor for this part of the molecule. In this paper they have also proposed a L-tryptophan as a source of the uracil-containing part of the molecule.[ citation needed ]

Study of the biosynthesis of the sparsomycin in a greater detail has revealed that L-cysteine and S-methyl group of methionine are real precursors for the monooxo-dithioacetal group. [8] These studies have also confirmed the L-tryptophan being a predecessor of the uracil moiety of the sparsomycin. However, it still remained unclear whether the transformation proceeds through the kynureine pathway or not. The next paper published by the same research group has shown that this pathway is not responsible for the transformations of L-tryphophan in the biosynthesis of sparsomycin. In this paper the authors have also confirmed (E)-3-(4-oxo-6-methyl-5-pyrimidinyl)acrylic acid (PCA) and (E)3-(2,4-dioxo-6-methyl-5-pyrimidinyl)acrylic acid (UCA) being intermediates in the studied biosynthetic pathway. [9] Several years later an enzyme, which catalyzes transformation of PCA to UCA was found. [10]

Sparsomycin retro.png
Sparsomycin biosynthesis.png

Related Research Articles

<span class="mw-page-title-main">Pyridoxal phosphate</span> Active form of vitamin B6

Pyridoxal phosphate (PLP, pyridoxal 5'-phosphate, P5P), the active form of vitamin B6, is a coenzyme in a variety of enzymatic reactions. The International Union of Biochemistry and Molecular Biology has catalogued more than 140 PLP-dependent activities, corresponding to ~4% of all classified activities. The versatility of PLP arises from its ability to covalently bind the substrate, and then to act as an electrophilic catalyst, thereby stabilizing different types of carbanionic reaction intermediates.

<span class="mw-page-title-main">Rifamycin</span> Group of antibiotics

The rifamycins are a group of antibiotics that are synthesized either naturally by the bacterium Amycolatopsis rifamycinica or artificially. They are a subclass of the larger family of ansamycins. Rifamycins are particularly effective against mycobacteria, and are therefore used to treat tuberculosis, leprosy, and mycobacterium avium complex (MAC) infections.

Nonribosomal peptides (NRP) are a class of peptide secondary metabolites, usually produced by microorganisms like bacteria and fungi. Nonribosomal peptides are also found in higher organisms, such as nudibranchs, but are thought to be made by bacteria inside these organisms. While there exist a wide range of peptides that are not synthesized by ribosomes, the term nonribosomal peptide typically refers to a very specific set of these as discussed in this article.

<span class="mw-page-title-main">Aminoacyl-tRNA</span>

Aminoacyl-tRNA is tRNA to which its cognate amino acid is chemically bonded (charged). The aa-tRNA, along with particular elongation factors, deliver the amino acid to the ribosome for incorporation into the polypeptide chain that is being produced during translation.

<span class="mw-page-title-main">Amino acid synthesis</span> The set of biochemical processes by which amino acids are produced

Amino acid synthesis is the set of biochemical processes by which the amino acids are produced. The substrates for these processes are various compounds in the organism's diet or growth media. Not all organisms are able to synthesize all amino acids. For example, humans can synthesize 11 of the 20 standard amino acids. These 11 are called the non-essential amino acids).

<span class="mw-page-title-main">Thiolase</span> Enzymes

Thiolases, also known as acetyl-coenzyme A acetyltransferases (ACAT), are enzymes which convert two units of acetyl-CoA to acetoacetyl CoA in the mevalonate pathway.

<span class="mw-page-title-main">Ribose-phosphate diphosphokinase</span> Class of enzymes

Ribose-phosphate diphosphokinase is an enzyme that converts ribose 5-phosphate into phosphoribosyl pyrophosphate (PRPP). It is classified under EC 2.7.6.1.

<span class="mw-page-title-main">Thienamycin</span> Chemical compound

Thienamycin is one of the most potent naturally produced antibiotics known thus far, discovered in Streptomyces cattleya in 1976. Thienamycin has excellent activity against both Gram-positive and Gram-negative bacteria and is resistant to bacterial β-lactamase enzymes. Thienamycin is a zwitterion at pH 7.

<span class="mw-page-title-main">Transsulfuration pathway</span>

The transsulfuration pathway is a metabolic pathway involving the interconversion of cysteine and homocysteine through the intermediate cystathionine. Two transsulfurylation pathways are known: the forward and the reverse.

<span class="mw-page-title-main">Biosynthesis of doxorubicin</span>

Doxorubicin (DXR) is a 14-hydroxylated version of daunorubicin, the immediate precursor of DXR in its biosynthetic pathway. Daunorubicin is more abundantly found as a natural product because it is produced by a number of different wild type strains of streptomyces. In contrast, only one known non-wild type species, streptomyces peucetius subspecies caesius ATCC 27952, was initially found to be capable of producing the more widely used doxorubicin. This strain was created by Arcamone et al. in 1969 by mutating a strain producing daunorubicin, but not DXR, at least in detectable quantities. Subsequently, Hutchinson's group showed that under special environmental conditions, or by the introduction of genetic modifications, other strains of streptomyces can produce doxorubicin. His group has also cloned many of the genes required for DXR production, although not all of them have been fully characterized. In 1996, Strohl's group discovered, isolated and characterized dox A, the gene encoding the enzyme that converts daunorubicin into DXR. By 1999, they produced recombinant Dox A, a Cytochrome P450 oxidase, and found that it catalyzes multiple steps in DXR biosynthesis, including steps leading to daunorubicin. This was significant because it became clear that all daunorubicin producing strains have the necessary genes to produce DXR, the much more therapeutically important of the two. Hutchinson's group went on to develop methods to improve the yield of DXR, from the fermentation process used in its commercial production, not only by introducing Dox A encoding plasmids, but also by introducing mutations to deactivate enzymes that shunt DXR precursors to less useful products, for example baumycin-like glycosides. Some triple mutants, that also over-expressed Dox A, were able to double the yield of DXR. This is of more than academic interest because at that time DXR cost about $1.37 million per kg and current production in 1999 was 225 kg per annum. More efficient production techniques have brought the price down to $1.1 million per kg for the non-liposomal formulation. Although DXR can be produced semi-synthetically from daunorubicin, the process involves electrophilic bromination and multiple steps and the yield is poor. Since daunorubicin is produced by fermentation, it would be ideal if the bacteria could complete DXR synthesis more effectively.

<span class="mw-page-title-main">Thiostrepton</span> Chemical compound

Thiostrepton is a natural cyclic oligopeptide antibiotic of the thiopeptide class, derived from several strains of streptomycetes, such as Streptomyces azureus and Streptomyces laurentii. Thiostrepton is a natural product of the ribosomally synthesized and post-translationally modified peptide (RiPP) class.

Streptogramin A is a group of antibiotics within the larger family of antibiotics known as streptogramins. They are synthesized by the bacteria Streptomyces virginiae. The streptogramin family of antibiotics consists of two distinct groups: group A antibiotics contain a 23-membered unsaturated ring with lactone and peptide bonds while group B antibiotics are depsipeptides. While structurally different, these two groups of antibiotics act synergistically, providing greater antibiotic activity than the combined activity of the separate components. These antibiotics have until recently been commercially manufactured as feed additives in agriculture, although today there is increased interest in their ability to combat antibiotic-resistant bacteria, particularly vancomycin-resistant bacteria.

<span class="mw-page-title-main">Endiandric acid C</span> Chemical compound

Endiandric acid C, isolated from the tree Endiandra introrsa, is a well characterized chemical compound. Endiadric acid C is reported to have better antibiotic activity than ampicillin.

<span class="mw-page-title-main">Apratoxin A</span> Chemical compound

Apratoxin A - is a cyanobacterial secondary metabolite, known as a potent cytotoxic marine natural product. It is a derivative of the Apratoxin family of cytotoxins. The mixed peptide-polyketide natural product comes from a polyketide synthase/non-ribosomal peptide synthase pathway (PKS/NRPS). This cytotoxin is known for inducing G1-phase cell cycle arrest and apoptosis. This natural product's activity has made it a popular target for developing anticancer derivatives.

Radical SAM is a designation for a superfamily of enzymes that use a [4Fe-4S]+ cluster to reductively cleave S-adenosyl-L-methionine (SAM) to generate a radical, usually a 5′-deoxyadenosyl radical (5'-dAdo), as a critical intermediate. These enzymes utilize this radical intermediate to perform diverse transformations, often to functionalize unactivated C-H bonds. Radical SAM enzymes are involved in cofactor biosynthesis, enzyme activation, peptide modification, post-transcriptional and post-translational modifications, metalloprotein cluster formation, tRNA modification, lipid metabolism, biosynthesis of antibiotics and natural products etc. The vast majority of known radical SAM enzymes belong to the radical SAM superfamily, and have a cysteine-rich motif that matches or resembles CxxxCxxC. rSAMs comprise the largest superfamily of metal-containing enzymes.

<span class="mw-page-title-main">Non-proteinogenic amino acids</span> Are not naturally encoded in the genome

In biochemistry, non-coded or non-proteinogenic amino acids are distinct from the 22 proteinogenic amino acids which are naturally encoded in the genome of organisms for the assembly of proteins. However, over 140 non-proteinogenic amino acids occur naturally in proteins and thousands more may occur in nature or be synthesized in the laboratory. Chemically synthesized amino acids can be called unnatural amino acids. Unnatural amino acids can be synthetically prepared from their native analogs via modifications such as amine alkylation, side chain substitution, structural bond extension cyclization, and isosteric replacements within the amino acid backbone. Many non-proteinogenic amino acids are important:

<span class="mw-page-title-main">Bottromycin</span> Chemical compound

Bottromycin is a macrocyclic peptide with antibiotic activity. It was first discovered in 1957 as a natural product isolated from Streptomyces bottropensis. It has been shown to inhibit methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) among other Gram-positive bacteria and mycoplasma. Bottromycin is structurally distinct from both vancomycin, a glycopeptide antibiotic, and methicillin, a beta-lactam antibiotic.

Ribosomally synthesized and post-translationally modified peptides (RiPPs), also known as ribosomal natural products, are a diverse class of natural products of ribosomal origin. Consisting of more than 20 sub-classes, RiPPs are produced by a variety of organisms, including prokaryotes, eukaryotes, and archaea, and they possess a wide range of biological functions.

<span class="mw-page-title-main">Nosiheptide</span> Chemical compound

Nosiheptide is a thiopeptide antibiotic produced by the bacterium Streptomyces actuosus.

<span class="mw-page-title-main">Gephyronic acid</span> Chemical compound

Gephyronic acid is a polyketide that exists as an equilibrating mixture of structural isomers. In nature, gephyronic acid is produced by slow growing myxobacterium: Archangium gephyra strain Ar3895 and Cystobacter violaceus strain Cb vi76. It is the first antibiotic in myxobacteria that was reported to specifically inhibit eukaryotic protein synthesis.

References

  1. Garrett R, Grisham CM (2013). Biochemistry. Brooks/Cole, Cengage Learning. ISBN   978-1133106296. OCLC   777722371.
  2. Ermolenko DN, Cornish PV, Ha T, Noller HF (February 2013). "Antibiotics that bind to the A site of the large ribosomal subunit can induce mRNA translocation". RNA. 19 (2): 158–66. doi:10.1261/rna.035964.112. PMC   3543091 . PMID   23249745.
  3. 1 2 Lazaro E, San Felix A, van den Broek LA, Ottenheijm HC, Ballesta JP (January 1991). "Interaction of the antibiotic sparsomycin with the ribosome". Antimicrobial Agents and Chemotherapy. 35 (1): 10–3. doi:10.1128/aac.35.1.10. PMC   244933 . PMID   2014963.
  4. A D Argoudelis, R R Herr, Antimicrob. Ag. Chemoth.780
  5. P Wiley, F MacKellar, J. Am. Chem. Soc.92(2) (1970), pp 417-418
  6. Total synthesis of the antibiotic sparsomycin, a modified uracil amino acid monoxodithioacetal, Harry C. J. Ottenheijm, Rob M. J. Liskamp, Simon P. J. M. Van Nispen, Hans A. Boots, Marian W. Tijhuis, J. Org. Chem.46 (16) (1981), pp 3273-3283
  7. Parry RJ, Eudy ME (1988). "The biosynthesis of sparsomycin. Elucidation of the origins of the carbon skeleton". J. Am. Chem. Soc. 110 (7): 2316–2317. doi:10.1021/ja00215a060.
  8. Parry RJ, Li Y, Gomez EE (1992). "Biosynthesis of the antitumor antibiotic sparsomycin". J. Am. Chem. Soc. 114 (15): 5946–5959. doi:10.1021/ja00041a007.
  9. Parry RJ, Hoyt JC, Li Y (1994). "The biosynthesis of sparsomycin. Further investigations of the biosynthesis of the uracil acrylic acid moiety". Tetrahedron Letters. 35 (41): 7497–7500. doi:10.1016/s0040-4039(00)78327-4.[ dead link ]
  10. Parry RJ, Hoyt JC (February 1997). "Purification and preliminary characterization of (E)-3-(2,4-dioxo-6-methyl-5-pyrimidinyl)acrylic acid synthase, an enzyme involved in biosynthesis of the antitumor agent sparsomycin". Journal of Bacteriology. 179 (4): 1385–92. doi:10.1128/jb.179.4.1385-1392.1997. PMC   178840 . PMID   9023226.